Dynavax Technologies Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Dynavax Technologies de 39.4% y 17.6% respectivamente, mientras que el BPA crecerá en un 37.2% al año.
Información clave
39.4%
Tasa de crecimiento de los beneficios
37.2%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 28.3% |
| Tasa de crecimiento de los ingresos | 17.6% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 08 Nov 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Dynavax Technologies: What The Stock Buyback Means, What It Doesn't
Nov 13Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Nov 12
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Oct 12Dynavax Technologies: Slow And Steady Wins The Race
Sep 05Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Aug 23Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Aug 14Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 384 | 70 | 69 | 96 | 4 |
| 12/31/2025 | 332 | 48 | 40 | 72 | 5 |
| 12/31/2024 | 277 | 26 | 7 | 18 | 5 |
| 9/30/2024 | 261 | 20 | 23 | 27 | N/A |
| 6/30/2024 | 250 | 17 | 35 | 39 | N/A |
| 3/31/2024 | 236 | 9 | 53 | 56 | N/A |
| 12/31/2023 | 232 | -6 | 96 | 101 | N/A |
| 9/30/2023 | 361 | 61 | 118 | 122 | N/A |
| 6/30/2023 | 459 | 111 | 147 | 152 | N/A |
| 3/31/2023 | 656 | 236 | 134 | 141 | N/A |
| 12/31/2022 | 723 | 293 | 56 | 63 | N/A |
| 9/30/2022 | 733 | 320 | 140 | 148 | N/A |
| 6/30/2022 | 674 | 228 | 142 | 153 | N/A |
| 3/31/2022 | 470 | 104 | 238 | 247 | N/A |
| 12/31/2021 | 439 | 72 | 326 | 336 | N/A |
| 9/30/2021 | 258 | -39 | 192 | 199 | N/A |
| 6/30/2021 | 163 | -6 | 101 | 105 | N/A |
| 3/31/2021 | 113 | -62 | -31 | -27 | N/A |
| 12/31/2020 | 40 | -75 | -103 | -92 | N/A |
| 9/30/2020 | 38 | -97 | -112 | -100 | N/A |
| 6/30/2020 | 35 | -138 | -115 | -94 | N/A |
| 3/31/2020 | 40 | -129 | -136 | -108 | N/A |
| 12/31/2019 | 35 | -156 | -151 | -121 | N/A |
| 9/30/2019 | 30 | -159 | -161 | -132 | N/A |
| 6/30/2019 | 21 | -163 | -166 | -144 | N/A |
| 3/31/2019 | 14 | -160 | -157 | -141 | N/A |
| 12/31/2018 | 8 | -159 | -146 | -131 | N/A |
| 9/30/2018 | 3 | -146 | -130 | -115 | N/A |
| 6/30/2018 | 1 | -128 | N/A | -99 | N/A |
| 3/31/2018 | 0 | -109 | N/A | -82 | N/A |
| 12/31/2017 | 0 | -95 | N/A | -78 | N/A |
| 9/30/2017 | 8 | -89 | N/A | -86 | N/A |
| 6/30/2017 | 8 | -102 | N/A | -97 | N/A |
| 3/31/2017 | 10 | -111 | N/A | -105 | N/A |
| 12/31/2016 | 11 | -112 | N/A | -107 | N/A |
| 9/30/2016 | 4 | -118 | N/A | -103 | N/A |
| 6/30/2016 | 5 | -113 | N/A | -97 | N/A |
| 3/31/2016 | 4 | -108 | N/A | -96 | N/A |
| 12/31/2015 | 4 | -107 | N/A | -93 | N/A |
| 9/30/2015 | 6 | -102 | N/A | -88 | N/A |
| 6/30/2015 | 7 | -102 | N/A | -88 | N/A |
| 3/31/2015 | 8 | -103 | N/A | -87 | N/A |
| 12/31/2014 | 11 | -91 | N/A | -74 | N/A |
| 9/30/2014 | 12 | -90 | N/A | -69 | N/A |
| 6/30/2014 | 12 | -76 | N/A | -58 | N/A |
| 3/31/2014 | 13 | -68 | N/A | -51 | N/A |
| 12/31/2013 | 11 | -75 | N/A | -59 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (39.4% al año) de DVAX es superior a la tasa de ahorro (2.6%).
Beneficios vs. Mercado: Se prevé que los beneficios (39.4% al año) de DVAX crezcan más rápidamente que el mercado US (15.2% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de DVAX crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (17.6% al año) de DVAX crezcan más rápidamente que los del mercado US (8.9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 17.6% al año) de DVAX crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de DVAX se prevé que sea elevada dentro de 3 años.